The emergence of compounds like copyright and Semaglutide signifies a remarkable shift in how we approach type 2 diabetes. These innovative therapies belong to a class known as GLP-1 action agonists, which duplicate the effects of a natural hormone that controls sugar levels and food intake. Initially, developed for diabetes, their effectiveness… Read More